Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the product's potentialManagement to host conference call at 8:00 AM Eastern time on Thursday, June 26, 2025Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2025) - Medexus Pharmaceuticals (TSX: MDP)...
2025-06-25 6:15 PM EDT
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26, 2025 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2025.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1...
2025-06-17 5:00 PM EDT
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government of Quebec for Trecondyv® (treosulfan for injection). The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.*"This development is another important reimbursement milestone for Trecondyv® because we have now achieved public reimbursement of Trecondyv® in Canada's three most populous provinces,...
2025-04-17 7:00 AM EDT
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States and announce company management's participation in two upcoming investor conferences.Medexus has seen an encouraging market response to GRAFAPEX™ in the weeks since the February 24 commercial launch of the product. Several procedures using commercially available GRAFAPEX™ have already occurred, which...
2025-04-07 7:00 AM EDT
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return responsibility for Gleolan® in the United States to NXDC as of a date no later than March 31, 2025. Under the terms of the termination agreement, Medexus will receive an agreed...
2025-03-14 7:00 AM EDT
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX™ (treosulfan) for Injection is now commercially available in the United States."We are pleased to report this positive development, which marks a strategically important step forward for our business and, importantly, will now benefit eligible patients across the United States," commented Ken d'Entremont, Medexus's Chief Executive Officer. "Not only will GRAFAPEX™ make a substantial contribution to alloHSCT in...
2025-02-24 7:00 AM EST
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2024 (the company's fiscal Q3 2025)....
2025-02-05 5:30 PM EST
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Programs will now reimburse eligible claims made for Trecondyv®, subject to satisfaction of any relevant conditions set out in the agreements.¹"This important development is another reimbursement milestone following the successful completion of the pCPA negotiation...
2025-02-04 7:00 AM EST
Medexus Schedules Third Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on February 5, 2025.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international...
2025-01-31 5:30 PM EST
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offering price of $4.00 per Common Share for aggregate gross proceeds to the Company of $30,000,000. The Offering was completed pursuant to an underwriting agreement dated January 28, 2025 between...
2025-01-31 8:38 AM EST
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 22, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the successful completion of the regulatory review process for GRAFAPEX™ (treosulfan) for injection with the US Food and Drug Administration and, in addition, to announce preliminary estimates of the company's operating and...
2025-01-22 10:59 AM EST
Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv® (treosulfan for injection) to be listed on the BC Cancer Benefit Drug List and funded through BC Cancer, a part of PHSA that provides a province-wide population-based cancer control program for the residents...
2025-01-15 7:00 AM EST
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - December 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a fourth amendment to its February 2021 exclusive license agreement with medac relating to commercialization of treosulfan in the United States.Among other things, the fourth amendment adjusts the unpaid regulatory milestone payments under the US treosulfan agreement. Upon an FDA approval of treosulfan, Medexus would repay a US$2.5 million credit received from medac...
2024-12-02 7:00 AM EST
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments.Reaching this important milestone on November 4, 2024 was the result of a collaborative negotiation process with pCPA,¹...
2024-11-18 7:00 AM EST
Medexus Announces Strong Fiscal Q2 2025 Results
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 millionManagement to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2024 (the company's fiscal Q2 2025)....
2024-11-07 5:30 PM EST
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second fiscal quarter ended September 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on November 7, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international...
2024-10-29 5:00 PM EDT
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.Detailed voting results for the election of directors are set out in the table below.
2024-09-19 5:30 PM EDT
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three months. The FDA has set a new PDUFA target action date of January 30, 2025.The FDA notified medac that the Agency requires additional time to review supplemental analyses of previously...
2024-09-16 7:30 AM EDT
Medexus Announces Strong Fiscal Q1 2025 Results
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2024 (the company's fiscal Q1 2025)....
2024-08-07 5:42 PM EDT
Medexus Schedules First Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on August 7, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international...
2024-07-30 5:30 PM EDT